A phase 2 study of axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma in Japan: 1-year follow-up and biomarker analysis

[1]  J. Liesveld,et al.  Cytopenia after CAR-T Cell Therapy—A Brief Review of a Complex Problem , 2022, Cancers.

[2]  T. Dorff,et al.  PD-L1 blockade restores CAR T cell activity through IFNγ-regulation of CD163+ macrophages , 2022, bioRxiv.

[3]  I. Flinn,et al.  Long-Term (≥4 Year and ≥5 Year) Overall Survival (OS) By 12- and 24-Month Event-Free Survival (EFS): An Updated Analysis of ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Refractory Large B-Cell Lymphoma (LBCL) , 2021, Blood.

[4]  K. Akashi,et al.  Phase 2 study of axicabtagene ciloleucel in Japanese patients with relapsed or refractory large B-cell lymphoma , 2021, International Journal of Clinical Oncology.

[5]  K. Davis,et al.  CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial , 2021, Nature Medicine.

[6]  E. Tholouli,et al.  OUTCOME OF LARGE B‐CELL LYMPHOMA PATIENTS FAILING CD19 TARGETED CAR‐T THERAPY , 2021, Hematological Oncology.

[7]  R. Davis,et al.  CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel , 2021, Blood.

[8]  John E. Mullinax,et al.  Tumor interferon signaling and suppressive myeloid cells associate with CAR T cell failure in large B cell lymphoma. , 2021, Blood.

[9]  R. Advani,et al.  Odronextamab (REGN1979), a Human CD20 x CD3 Bispecific Antibody, Induces Durable, Complete Responses in Patients with Highly Refractory B-Cell Non-Hodgkin Lymphoma, Including Patients Refractory to CAR T Therapy , 2020 .

[10]  D. Cunningham,et al.  Subcutaneous Epcoritamab Induces Complete Responses with an Encouraging Safety Profile across Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Subtypes, Including Patients with Prior CAR-T Therapy: Updated Dose Escalation Data , 2020 .

[11]  D. Miklos,et al.  Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. , 2020, Blood advances.

[12]  R. Gonzalez,et al.  Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel , 2020, Clinical Cancer Research.

[13]  C. Jacobson,et al.  Retreatment (reTx) of patients (pts) with refractory large B-cell lymphoma with axicabtagene ciloleucel (axi-cel) in ZUMA-1. , 2020 .

[14]  L. Sehn,et al.  Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines. , 2019, Blood.

[15]  Justin R. Klesmith,et al.  Fine epitope mapping of the CD19 extracellular domain promotes design. , 2019, Biochemistry.

[16]  S. Neelapu.  Managing the toxicities of CAR T‐cell therapy , 2019, Hematological oncology.

[17]  R. Levy,et al.  Axicabtagene Ciloleucel CAR T‐Cell Therapy in Refractory Large B‐Cell Lymphoma , 2017, The New England journal of medicine.

[18]  J. Cerhan,et al.  Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. , 2017, Blood.

[19]  D. Miklos,et al.  Characterization of anti-CD19 chimeric antigen receptor (CAR) T cell-mediated tumor microenvironment immune gene profile in a multicenter trial (ZUMA-1) with axicabtagene ciloleucel (axi-cel, KTE-C19). , 2017 .

[20]  Moriah H Nissan,et al.  OncoKB: A Precision Oncology Knowledge Base. , 2017, JCO precision oncology.

[21]  A. Butte,et al.  xCell: digitally portraying the tissue cellular heterogeneity landscape , 2017, bioRxiv.

[22]  R. Xiang,et al.  M2 tumour-associated macrophages contribute to tumour progression via legumain remodelling the extracellular matrix in diffuse large B cell lymphoma , 2016, Scientific Reports.

[23]  Robert Gentleman,et al.  Prediction and Quantification of Splice Events from RNA-Seq Data , 2016, PloS one.

[24]  R. Advani,et al.  The World Health Organization Classification of Lymphoid Neoplasms , 2013 .

[25]  O. Hofmann,et al.  VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research , 2016, Nucleic acids research.

[26]  S. Grupp,et al.  Current concepts in the diagnosis and management of cytokine release syndrome. , 2014, Blood.

[27]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[28]  Justin Guinney,et al.  GSVA: gene set variation analysis for microarray and RNA-Seq data , 2013, BMC Bioinformatics.

[29]  W. Wilson,et al.  B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. , 2012, Blood.

[30]  Colin N. Dewey,et al.  RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome , 2011, BMC Bioinformatics.

[31]  S. Thompson,et al.  Two-stage designs optimal under the alternative hypothesis for phase II cancer clinical trials , 2010, Contemporary clinical trials.

[32]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[33]  L. Staudt,et al.  Stromal gene signatures in large-B-cell lymphomas. , 2008, The New England journal of medicine.

[34]  Sigrid Stroobants,et al.  Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  A. Mantovani,et al.  Macrophage‐derived chemokine (MDC) , 2000, Journal of leukocyte biology.